Literature DB >> 1825633

Human transferrin allows efficient IgE production by anti-CD3-stimulated human lymphocytes at low cell densities.

T Van der Pouw-Kraan1, C Van Kooten, R Van Oers, L A Aarden.   

Abstract

A solid-phase-coupled anti-CD3 T cell activation system was used to study the regulation of human IgE production in vitro. Using 5000 peripheral blood lymphocytes from healthy donors, containing 10%-20% B lymphocytes and no monocytes. IgE was produced very efficiently on a per cell basis. A key observation was that apart from interleukin (IL) 4, human transferrin was essential for IgE production. Furthermore it was found that IgE was produced at low densities only; at higher cell concentrations IgE production was completely abrogated, whereas IgM production increased with increasing cell density. This inhibition at higher cell densities is probably mediated by IL2. Addition of low amounts (6 U/ml) of IL2 strongly enhanced IgE and IgM production at low cell densities, but higher concentrations of IL2 (50 U/ml) were strongly inhibitory for IgE production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825633     DOI: 10.1002/eji.1830210220

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  In vitro production of IgG4 by peripheral blood mononuclear cells (PBMC): the contribution of committed B cells.

Authors:  B A de Boer; Y C Kruize; M Yazdanbakhsh
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

2.  Interleukin-12 suppresses immunoglobulin E production but enhances immunoglobulin G4 production by human peripheral blood mononuclear cells.

Authors:  B A de Boer; Y C Kruize; P J Rotmans; M Yazdanbakhsh
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin.

Authors:  C T Van der Pouw-Kraan; H J Rensink; R Rappuoli; L A Aarden
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.